Stroke treatment guidelines should be re-written to remove DOAC recent use as a contraindication to thrombolysis, Australian neurologists say. Dr Geoffrey Herkes and Dr Chee Hoou Loh make the recommendation in their report of a patient with acute ischaemic stroke who had rapid reversal of dabigatran with idarucizumab (Praxbind) prior to successful thrombolysis. The 77-year ...
Already a member?
Enter your email to keep reading.